US FDA reverses course, will review Moderna's flu vaccine application
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The US FDA has reversed its previous stance and will review Moderna's flu vaccine application. The vaccine in question is based on mRNA technology. The decision marks a change in the FDA's approach to reviewing the vaccine application, though details of the initial decision and the reversal are not specified.
Full coverage
1
NPR·Feb 182
The Guardian·Feb 183
CNBC·Feb 184
CIDRAP·Feb 185
CNN·Feb 186
The American Journal of Managed Care® (AJMC®)·Feb 187
The New York Times·Feb 188
STAT·Feb 18